THE LONG DAWN

DISPATCHES FROM THE FRONTIER OF HUMAN LIFE

The first light of a longer human age

Every week, somewhere on Earth, a trial pushes the edge of what a human life can be. We record each one: what was tested, how far it has climbed, and what is still unknown. Every claim is linked to its source.

The Ascent

Every discovery climbs the same five steps

We label each dispatch by how far its evidence has climbed, so a first glimmer is never mistaken for daylight. How to read the evidence

  1. Lab & animalFirst lightCells or animals only. Most never reach people.
  2. Phase 1First stepsFirst in humans. Small, mainly safety and dose.
  3. Phase 2Early signalDoes it work? Hundreds of people, early efficacy.
  4. Phase 3Weight of manyTested at scale, usually randomized against standard care.
  5. ApprovedIn the worldA regulator (FDA, EMA, Health Canada) has authorized it.

Latest dispatches

What moved this season

Approvals, phase 3 results and first-in-human signals, newest first. Filter by frontier.

Cancer

ERAS‑0015 shrank tumours in early pancreatic and lung cancer testing

For forty years the RAS protein was called undruggable. A second molecule built to reach it is now being tested in people.

Phase 1Company-reported · not peer reviewed
Rare disease

First treatment approved for the neurological symptoms of type 3 Gaucher disease

A small molecule that crosses the blood-brain barrier, reaching where earlier treatments could not.

ApprovedRegulator decision
Rare disease

First drug shown to help children with infantile-onset Niemann-Pick disease type C live longer

For a disease that once only took, the first treatment that gives back years.

ApprovedRegulator decision
Cancer

FDA grants accelerated approval to neladalkib for ALK-positive lung cancer after earlier therapy

Each generation of targeted drug reaches further down the same road.

ApprovedRegulator decision
Heart & metabolism

First factor XIa blood thinner approved to cut the risk of a second stroke

A new class of clot prevention, tested on more than twelve thousand people.

ApprovedRegulator decision
Gene & cell

First plasmid DNA immunotherapy approved in the US, for a rare HPV airway disease

Small loops of DNA that teach the body to hunt a virus: a new kind of medicine enters the clinic.

ApprovedRegulator decision
Brain & nerves

Clot removal 24 to 72 hours after a major stroke improved recovery, with more bleeding

The window to save a brain, once measured in hours, is being measured in days.

Phase 3Peer-reviewed journal
Brain & nerves

Remibrutinib cut relapses versus teriflunomide in two phase 3 multiple sclerosis trials

A new oral class against multiple sclerosis, tested on two thousand people across 46 countries.

Phase 3Peer-reviewed journal
Heart & metabolism

Retatrutide reduced sleep apnea severity in two phase 3 trials

One weekly injection reshaping the body's metabolism, and with it the quiet emergencies of sleep.

Phase 3Peer-reviewed journal
Cancer

Immunotherapy alone may let some rectal cancer patients skip surgery, radiation and chemotherapy

For a few, the cure may no longer require the knife.

ApprovedRegulator decision
Cancer

Daraxonrasib doubled median survival in previously treated pancreatic cancer, and the FDA approved it

The first drug to strike RAS across its many mutations has crossed from trial to treatment.

ApprovedPeer-reviewed journal
Mind & machine

A man with ALS used a brain implant at home for nearly two years to speak and work, unassisted

Thought becomes speech, every day, in an ordinary home. Mind and machine are learning to share a voice.

Phase 1Peer-reviewed journal

Why we keep this record

Science and machine are rewriting the terms of a human life. Someone should keep the record, honestly.

We are optimists with receipts. The Long Dawn is lofty about where humanity is going and plain about where each result stands today. Early signals are labeled early. Company claims are labeled as claims. Risks are printed beside the hope.

Read the manifesto